NOXA1

NOXA1 is a cytosolic activator of the NOX1 NADPH oxidase complex that drives superoxide production in diverse cell types including vascular smooth muscle, colon epithelium, and renal tubular cells. NOXA1 binds Nox1 through its activation domain and associates with NOXO1 and p22phox to assemble the active membrane oxidase complex; its SH3 domain modulates the kinetics of complex formation rather than being strictly required for catalysis (PMID:17602954, PMID:20454568, PMID:24187133). NOXA1 activity is positively regulated by c-Src phosphorylation at Tyr110 (enabling Tks4 binding and invadopodia formation) and negatively regulated by PKA/PKC/MAPK phosphorylation at Ser172, Ser282, and Ser461, which reduce Nox1 and Rac1 binding and promote 14-3-3-dependent sequestration away from the membrane (PMID:17913709, PMID:20110267, PMID:20943948). Beyond NOX1 activation, NOXA1 inhibits Duox1-dependent H₂O₂ production in airway epithelium (PMID:18606821), mediates angiotensin II-dependent ENaC activation and sodium homeostasis in the distal nephron (PMID:36201326, PMID:34714114), and drives TNFα-induced VSMC phenotypic switching during atherogenesis (PMID:30576919).

1. 2006 Medium

   Establishing that NOXA1 is a cytosolic activator that translocates to the membrane with NOXO1 and is required for agonist-induced ROS in vascular smooth muscle cells answered where and how NOXA1 participates in NOX1 complex assembly.

   Evidence Western blot fractionation, fluorescent fusion protein imaging, and antisense knockdown with ROS assay in mouse VSMC

   PMID:16814099

   Open questions at the time

   • Single-lab antisense approach without genetic confirmation
   • Stimulus-specific versus constitutive role not delineated
   • Stoichiometry of NOXA1 in the membrane complex undefined
2. 2007 High

   Dissecting NOXA1 domain requirements revealed that the activation domain is essential for NOX1 catalysis while the SH3 domain tunes kinetics, and identified a dominant-negative splice variant (NOXA1inhib) that blocks complex assembly.

   Evidence Systematic deletion/point mutants in K562 cells stably expressing NOX1/NOXO1 with kinetic superoxide assays and co-immunoprecipitation

   PMID:17602954

   Open questions at the time

   • Structural basis of activation domain–Nox1 interface unresolved
   • Physiological relevance of NOXA1inhib splice variant not tested in vivo
3. 2007 High

   Identification of PKA-mediated phosphorylation at Ser172 and Ser461 as a negative regulatory mechanism—promoting 14-3-3 binding and membrane dissociation—established how cAMP signaling restrains NOX1 activity.

   Evidence Site-directed mutagenesis, phosphopeptide mapping, co-IP, and cAMP manipulation in HEK293 and colon cell lines

   PMID:17913709

   Open questions at the time

   • In vivo confirmation of 14-3-3 sequestration in tissues not provided
   • Identity of phosphatase(s) reversing these modifications unknown
4. 2008 High

   Demonstrating that NOXA1 inhibits Duox1-dependent H₂O₂ in airway epithelium expanded NOXA1's role beyond NOX1 activation to a dual-oxidase inhibitory function governed by calcium-dependent dissociation.

   Evidence Reconstituted cell-free system, mutational analysis, and Duox1 knockdown in mucociliary airway epithelial model

   PMID:18606821

   Open questions at the time

   • Binding interface between NOXA1 and Duox1 uncharacterized
   • Whether this inhibitory role extends to Duox2 untested
5. 2010 High

   Mapping MAPK-dependent Ser282 and PKC-dependent Ser172 phosphorylation as additional negative regulatory sites that reduce Nox1 and Rac1 binding established a multi-kinase brake preventing NOX1 hyperactivation.

   Evidence In vitro kinase assays, site-directed mutagenesis, phosphopeptide mapping, and ROS assays in HEK293 cells

   PMID:20110267

   Open questions at the time

   • Combinatorial effects of simultaneous multi-site phosphorylation not resolved
   • In vivo validation lacking
6. 2010 High

   c-Src phosphorylation at Tyr110 was shown to be required for NOXA1–Tks4 interaction, Nox1-dependent ROS, and invadopodia formation, linking NOXA1 to cancer cell invasion.

   Evidence Phosphomimetic/unphosphorylable mutants, co-IP, ROS assay, and ECM degradation assay in human colon cancer cells

   PMID:20943948

   Open questions at the time

   • Whether Tyr110 phosphorylation and Ser172/282/461 phosphorylation are coordinated remains unknown
   • In vivo tumor invasion phenotype not tested
7. 2010 High

   Quantitative biophysical characterization showed that NOXA1 and NOXO1 both interact with p22phox, with NOXO1's C-terminal tail competing for p22phox binding—establishing how complex assembly is regulated at the membrane anchor.

   Evidence Isothermal titration calorimetry and pulldown assays

   PMID:20454568

   Open questions at the time

   • Ternary complex structure of NOXA1–NOXO1–p22phox not determined
   • Relative affinities under physiological membrane conditions unknown
8. 2013 High

   Development of the NoxA1ds peptide inhibitor that selectively disrupts the Nox1–NOXA1 activation domain interaction confirmed that this interface is the obligate catalytic trigger and provided an isoform-specific pharmacological tool.

   Evidence Cell-free Nox1 reconstitution, FRET, FRAP, ELISA, and confocal microscopy

   PMID:24187133

   Open questions at the time

   • In vivo pharmacokinetics and efficacy of NoxA1ds not characterized in this study
   • Atomic-level binding interface undefined
9. 2013 High

   PKC-dependent phosphorylation of NOXO1 at Thr341 was shown to be required for sufficient NOXO1–NOXA1 interaction and PMA-stimulated superoxide, revealing bidirectional phospho-regulation of the organizer–activator pair.

   Evidence In vitro phosphorylation, alanine mutagenesis, pulldown and superoxide assays

   PMID:23957209

   Open questions at the time

   • Whether NOXO1 Thr341 and NOXA1 Ser172 phosphorylation are antagonistic in the same cell context unknown
10. 2014 High

    PKCβ1-dependent Nox1 Thr429 phosphorylation was shown to enhance Nox1 association with the NOXA1 activation domain, demonstrating that signal-dependent modifications on Nox1 itself license activator recruitment.

    Evidence Mass spectrometry, ITC, siRNA, mutagenesis in TNFα-stimulated VSMC

    PMID:25228390

    Open questions at the time

    • Whether other stimuli use the same Thr429 mechanism untested
    • Structural consequences of Thr429 phosphorylation unresolved
11. 2018 High

    Conditional Noxa1 knockout in smooth muscle cells demonstrated that NOXA1/NOX1 drives TNFα-induced VSMC proliferation, migration, and KLF4-mediated macrophage-like phenotypic switching during atherogenesis in vivo.

    Evidence Systemic and SMC-specific Noxa1 KO mice in vascular injury and atherosclerosis (Apoe−/−, Ldlr−/−) models

    PMID:30576919

    Open questions at the time

    • Whether endothelial NOXA1 contributes independently to atherogenesis not addressed
    • Downstream ROS targets mediating KLF4 induction unidentified
12. 2022 High

    Cell-type-specific Noxa1 deletion and electrophysiology in kidney revealed that NOXA1/NOX1-derived ROS activate ENaC in distal nephron principal cells downstream of angiotensin II, establishing a renal sodium-handling function with sex-dependent regulation.

    Evidence Principal cell-specific Noxa1 KO mice, patch-clamp electrophysiology, NOX1 inhibitor ML171, losartan, telemetric blood pressure, Na+ excretion

    PMID:34714114 PMID:36201326

    Open questions at the time

    • Direct ROS target linking NOX1 output to ENaC channel gating unidentified
    • Whether NOXA1 controls other renal ion channels unknown
    • Basis of sex-specific regulation at the molecular level unresolved

• A high-resolution structural model of the NOXA1–Nox1 activation domain interface is lacking, and the precise ROS-sensing intermediates downstream of NOXA1/NOX1 that trigger ENaC activation, KLF4 induction, and invadopodia signaling remain undefined.
• No crystal or cryo-EM structure of NOXA1 alone or in complex
• Direct oxidation targets linking NOX1-derived superoxide to downstream effectors (ENaC, KLF4) uncharacterized
• In vivo relevance of NOXA1 multi-site phosphorylation crosstalk not tested